Inflammation, fibrosis, cirrhosis and hepatocellular carcinoma (HCC) risk.
The Glyco Liver Profile is a unique, non-invasive test that provides the clinician with a full picture of liver health regardless of aetiology — all from a single blood sample.
This innovative test addresses the medical and economic costs of chronic liver disease — accounting for approximately 2% of deaths annually — streamlining patient stratification and risk assessment, and improving clinical management and treatment outcomes.
Glyco Liver Profile enables patient risk assessment, monitoring, diagnosis and 5-year prediction of hepatocellular carcinoma (HCC) development using four glycan biomarkers which together provide a clear insight into liver health.
Helena Biosciences have a full programme of events and opportunities throughout the year in support of our Glyco Liver Profile product launch. If you would like to take part, or collaborate with us on studies, evaluations or more, please get in touch using the form below.
Glyco Liver Profile joins a range of existing tests running on our fully-automated V8 NEXUS capillary electrophoresis system.